Hims & Hers Launches Canadian Operations Ahead of Generic GLP-1s
US telemedicine company Hims & Hers has launched operations in Canada, positioning itself ahead of expected generic semaglutide availability in mid-2026.
Strategic Canadian Market Entry
The direct-to-consumer healthcare platform's expansion into Canada comes as Health Canada reviews nine generic semaglutide applications. The company specializes in online consultations and prescription delivery services, offering an alternative distribution channel for medications including future generic versions of Ozempic and Wegovy.
Hims & Hers' Canadian launch coincides with growing demand for GLP-1 medications, with recent surveys indicating approximately 3 million Canadians currently use these drugs. The company's telemedicine model could provide expanded access once generic alternatives become available.
Generic Competition Timeline
Health Canada's generic semaglutide tracker shows nine manufacturers have submitted applications for generic versions. Patent protection expired January 4, 2026, clearing the regulatory pathway for generic competition.
Current brand-name pricing in Canada ranges from $300-400 monthly for semaglutide medications. Industry analysts project generic versions could reduce costs by 65% or more, potentially bringing monthly prices down to $100-150.
Telemedicine Distribution Model
The company's Canadian operations will follow its US model of online consultations followed by direct medication delivery. This approach could complement traditional pharmacy distribution channels for both current brand-name products and future generic alternatives.
Canadian patients currently access GLP-1 medications through traditional pharmacies including Shoppers Drug Mart, Costco, and Walmart. Hims & Hers' entry adds a digital-first option that could particularly benefit patients in remote areas with limited pharmacy access.
Market Timing and Competition
The launch timing appears strategic, as Health Canada is expected to approve the first generic semaglutide applications between May and September 2026. Early market entry allows the company to establish patient relationships before generic availability increases market competition.
Several Canadian companies are also preparing for generic semaglutide availability, including Vimy Pharma, which plans to file its application in coming weeks. The company aims to produce domestically-manufactured generic semaglutide.
Regulatory Considerations
Hims & Hers must comply with Canadian healthcare regulations, including provincial licensing requirements for telemedicine services. The company will need to work within each province's regulatory framework for online prescription services.
Patients considering telemedicine services for GLP-1 medications should verify their provincial insurance coverage checker status and consult the FAQ section for coverage details.
Industry Impact
The expansion reflects growing investor confidence in Canada's GLP-1 market potential. With generic competition expected to significantly expand patient access through reduced pricing, companies are positioning for increased market demand.
Traditional pharmacy chains and online platforms will compete for market share as generic alternatives become available. The combination of lower prices and multiple distribution channels could substantially increase GLP-1 medication accessibility across Canada.
This article is for informational purposes only and does not constitute medical advice.
Get notified when generic prices go live
We’ll send one email the moment generic semaglutide prices are listed at Canadian pharmacies. No spam.
Get notified when generic semaglutide becomes available in Canada
Expected Q3 2026 — be the first to know
